A Phase 2 interventional study of ZD4054 15 mg and Placebo in Prostate Cancer, sponsored by AstraZeneca. Completed at 60 sites in 14 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-08.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 16th largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2004, is one of 16 in phase 2, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 18 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Australia, Germany and 4 more countries
Ages 18–99 · Men only
AstraZeneca · Sites in United States, Australia, Korea, Republic of
Ages 18–100 · Men only
AstraZeneca · Sites in United States, Australia, Austria and 21 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Brazil, China and 7 more countries
Ages 18–130 · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 17 · Phase 4 4
First in 1994; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 447 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 110 across the 60 interventional studies, 310 across the 29 observational. Of the 58 that completed or were terminated, 11 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
8 of the studies in Prostatic Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06120491Phase 3AstraZenecaSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | 2027-09-30 |
| NCT06267729AstraZenecaStudy of AZD0754 in Participants With Metastatic Prostate Cancer | 2026-11-24 |
| NCT06402331Fusion Pharmaceuticals Inc.FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2026-12-23 |
| NCT06380738AstraZenecaReal-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) | 2027-02-14 |
| NCT07560215AstraZenecaPROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill). The study will also provide further information on the safety of ZD4054 (Zibotentan).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo oral tablet once daily, with best supportive care
Drug: Placebo
ZD4054 10 mg oral tablet once daily, with best supportive care
Drug: ZD4054 10 mg
ZD4054 15 mg oral tablet once daily, with best supportive care
Drug: ZD4054 15 mg
15 mg oral tablet once daily
Also known as: Zibotentan
10mg oral tablet once daily
Also known as: (Zibotentan)
Time to Progression (TTP)
Median time (in days) from randomisation until disease progression, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline or death using the Kaplan-Meier method.
Time frame: Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008).
Time to Death
Median time (in days) from randomisation until death using the Kaplan-Meier method.
Time frame: Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. After progression survival was assessed 6-monthly. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008).
Change in Total Prostate Specific Antigen (PSA) Over Time
Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to 12 weeks.
Time frame: Baseline to 12 weeks. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006).
Objective Response Rate (ORR)
Using the Response Evaluation Criteria in Solid Tumours (RECIST), an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR), which is subsequently confirmed as per RECIST. Objective Response Rate (ORR) is defined as the percentage of patients with OR.
Time frame: For patients with measurable disease at baseline, Response Evaluation Criteria in Solid Tumours (RECIST) scans were 12-weekly from randomisation. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006).
Change in Number of Bone Metastases Over Time
Percentage change in the number of bone metastases from baseline to last available post-baseline scan prior to discontinuation.
Time frame: Baseline to last available post-baseline scan prior to discontinuation, up to maximum of 1164 days.
447 patients with prostate cancer who had bone metastases with no pain or mild symptoms of pain and a rising serum Prostate Specific Antigen (PSA), despite a serum testosterone of \<= 2.4 nmol/L (70 ng/dL), were recruited between 14th July 2004 and 10th January 2006.
| Milestone | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| Started | 107 | 107 | 98 |
| Received study treatment. | 107 | 107 | 98 |
| Completed | 1 | 0 | 2 |
| Not completed | 106 | 107 | 96 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 7 | 7 | 6 |
| Withdrew: Study-specific discontinuation criteria | 75 | 74 | 62 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 0 | 1 |
| Withdrew: Consent expired | 7 | 10 | 9 |
| Withdrew: Reasons not specified | 2 | 1 | 1 |
| Withdrew: Continuing on study off treatment | 14 | 13 | 16 |
Median time (in days) from randomisation until disease progression, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline or death using the Kaplan-Meier method.
| Days | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| Time to Progression (TTP) | 111 (77 to 252) | 138 (80 to 247) | 113 (80 to 279) |
Median time (in days) from randomisation until death using the Kaplan-Meier method.
| Days | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| Time to Death | 596 (317 to 893) | 706 (457 to 1043) | 717 (452 to 1232) |
Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to 12 weeks.
| Percentage Change in PSA | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| Change in Total Prostate Specific Antigen (PSA) Over Time | 110.4 ± 179.16 | 131.6 ± 454.35 | 69.34 ± 99.14 |
Using the Response Evaluation Criteria in Solid Tumours (RECIST), an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR), which is subsequently confirmed as per RECIST. Objective Response Rate (ORR) is defined as the percentage of patients with OR.
| percentage of participants | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| Objective Response Rate (ORR) | 0 | 0 | 0 |
Percentage change in the number of bone metastases from baseline to last available post-baseline scan prior to discontinuation.
| Percentage Change | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| Change in Number of Bone Metastases Over Time | 187.1 ± 212.6 | 113.4 ± 195.6 | 189 ± 245.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 26/107 (24.3%) | 93/107 (86.9%) |
| ZD4054 10 mg | — | 18/107 (16.8%) | 86/107 (80.4%) |
| ZD4054 15 mg | — | 16/98 (16.3%) | 87/98 (88.8%) |
| Event | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/107 | 3/107 | 1/98 |
| Cardiac FailureCardiac disorders | 0/107 | 3/107 | 0/98 |
| Myocardial InfarctionCardiac disorders | 0/107 | 1/107 | 2/98 |
| HaematuriaRenal and urinary disorders | 0/107 | 1/107 | 2/98 |
| Cardiopulmonary FailureCardiac disorders | 0/107 | 2/107 | 0/98 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/107 | 0/107 | 0/98 |
| VomitingGastrointestinal disorders | 1/107 | 0/107 | 1/98 |
| Abdominal Pain UpperGastrointestinal disorders | 0/107 | 0/107 | 1/98 |
| ConstipationGastrointestinal disorders | 0/107 | 0/107 | 1/98 |
| Gastric Ulcer HaemorrhageGastrointestinal disorders | 0/107 | 0/107 | 1/98 |
| Event | Placebo | ZD4054 10 mg | ZD4054 15 mg |
|---|---|---|---|
| Oedema PeripheralGeneral disorders | 47/107 | 42/107 | 11/98 |
| HeadacheNervous system disorders | 44/107 | 39/107 | 13/98 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 34/107 | 31/107 | 4/98 |
| NauseaGastrointestinal disorders | 13/107 | 19/107 | 20/98 |
| ConstipationGastrointestinal disorders | 11/107 | 13/107 | 18/98 |
| Back PainMusculoskeletal and connective tissue disorders | 19/107 | 18/107 | 17/98 |
| FatigueGeneral disorders | 7/107 | 18/107 | 10/98 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/107 | 17/107 | 6/98 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 15/107 | 17/107 | 3/98 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 7/107 | 10/107 | 12/98 |
| Age Continuous(years) | Placebo | ZD4054 10 mg | ZD4054 15 mg | Total |
|---|---|---|---|---|
| Mean | 71 ± 9 | 70 ± 8 | 69 ± 8 | 70 ± 9 |
| Sex: Female, Male(Participants) | Placebo | ZD4054 10 mg | ZD4054 15 mg | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 107 | 107 | 98 | 312 |
| Race/Ethnicity, Customized(Participants) | Placebo | ZD4054 10 mg | ZD4054 15 mg | Total |
|---|---|---|---|---|
| Caucasian | 106 | 107 | 93 | 306 |
| Black | 0 | 0 | 1 | 1 |
| Oriental | 1 | 0 | 3 | 4 |
| Other | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | ZD4054 10 mg | ZD4054 15 mg | Total |
|---|---|---|---|---|
| Hispanic | 3 | 4 | 3 | 10 |
| African-American | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 3 | 4 |
| Japanese | 0 | 0 | 1 | 1 |
| Not a specific ethnic group | 99 | 95 | 87 | 281 |
| Other | 4 | 8 | 3 | 15 |
The record gives a start of Jul 2004, a primary completion of Dec 2008 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 3 years 9 months after primary completion. A results delay was requested in May 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054